{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:01:41Z","timestamp":1756461701865,"version":"3.43.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[1998,5]]},"DOI":"10.1023\/a:1008887708104","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T11:51:56Z","timestamp":1040557916000},"page":"191-202","source":"Crossref","is-referenced-by-count":22,"title":["Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb\/IIIa Receptor Inhibitors?"],"prefix":"10.1007","volume":"5","author":[{"given":"Robert P.","family":"Giugliano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"160718_CR1","volume-title":"1994 Summary: National Hospital Discharge Survey. Advance Data from Vital and Health Statistics","author":"EJ Graves","year":"1996","unstructured":"Graves EJ, Gillum BS. 1994 Summary: National Hospital Discharge Survey. Advance Data from Vital and Health Statistics: no. 278. Hyattsville, MD: National Center for Health Statistics, 1996."},{"key":"160718_CR2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0735-1097(94)90634-3","volume":"23","author":"RA Harrington","year":"1994","unstructured":"Harrington RA, Sane DC, Califf RM, et al. for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1994:23:891\u2013898.","journal-title":"J Am Coll Cardiol"},{"key":"160718_CR3","first-page":"33","volume":"21","author":"L. Selling","year":"1910","unstructured":"Selling L. A preliminary report of some cases of purpura hemorrhagica due to benzol poisoning. Johns Hopkins Hosp Bull 1910:21:33.","journal-title":"Johns Hopkins Hosp Bull"},{"key":"160718_CR4","first-page":"249","volume":"7","author":"JF. Ackroyd","year":"1949","unstructured":"Ackroyd JF. The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedermoid. Clin Sci 1949:7: 249\u2013248.","journal-title":"Clin Sci"},{"key":"160718_CR5","doi-asserted-by":"crossref","unstructured":"Miescher P, Cooper N. The fixation of soluble antigen-antibody complexes upon thrombocytes. Vox Sang 1960: 5138\u20135142.","DOI":"10.1159\/000478552"},{"key":"160718_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.107.5.711","volume":"17","author":"NR. Schulman","year":"1958","unstructured":"Schulman NR. Immunoreactions involving platelets. IV. Studies on the pathogenesis of thrombocytopenia in drug purpura using test doses of quinidine in sensitized individuals: Their implications in idiopathic thrombocytopenic purpura. J Exp Med 1958:17:711\u2013729.","journal-title":"J Exp Med"},{"key":"160718_CR7","first-page":"562","volume":"80","author":"H. Denning","year":"1933","unstructured":"Denning H. Thrombopenische purpura nach iodeinnahme. Munch Med Wsch 1933:80:562.","journal-title":"Munch Med Wsch"},{"key":"160718_CR8","first-page":"1501","volume-title":"Hematology: Basic Principles and Practice","author":"MS Trimble","year":"1991","unstructured":"Trimble MS, Warkentin TE, Kelton JG. Thrombocytopenia due to platelet destruction and hypersplenism. In: Hoffman R, ed. Hematology: Basic Principles and Practice. New York: Churchill Livingstone, 1991:1501\u20131513."},{"key":"160718_CR9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/0140-6736(90)92558-Y","volume":"336","author":"Y Gruel","year":"1990","unstructured":"Gruel Y, Lang M, Darnige L, et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990:336:1077\u2013108.","journal-title":"Lancet"},{"key":"160718_CR10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0268-960X(88)90032-X","volume":"2","author":"BH. Chong","year":"1988","unstructured":"Chong BH. Heparin-induced thrombocytopenia. Blood Rev 1988:2:108\u2013114.","journal-title":"Blood Rev"},{"key":"160718_CR11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.1995.tb08346.x","volume":"89","author":"BH. Chong","year":"1995","unstructured":"Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995:89:431\u2013439.","journal-title":"Br J Haematol"},{"key":"160718_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0889-8588(18)30515-X","volume":"4","author":"TE Warkentin","year":"1990","unstructured":"Warkentin TE, Kelton JG. Heparin and platelets. Hema Oncol Clin North Am 1990:4:243\u2013264.","journal-title":"Hema Oncol Clin North Am"},{"issue":"Suppl.","key":"160718_CR13","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.1378\/chest.108.4_Supplement.258S","volume":"108","author":"J Hirsh","year":"1995","unstructured":"Hirsh J, Raschke R, Warkentin TE, Dalen J, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995:108(Suppl.):258S\u2013275S.","journal-title":"Chest"},{"key":"160718_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJM197607292950501","volume":"295","author":"RB Babcock","year":"1976","unstructured":"Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976:295:237.","journal-title":"N Engl J Med"},{"key":"160718_CR15","first-page":"125","volume":"6","author":"PL Cimo","year":"1979","unstructured":"Cimo PL, Moake JL, Weinger RS, et al. Heparin-induced thrombocytopenia: Association with a platelet-aggregating factor and arterial thromboses. Am J Metabol 1979:6:125.","journal-title":"Am J Metabol"},{"key":"160718_CR16","unstructured":"Turpie AGG. The pharmacology of low-molecular weight heparin. The International Cardiology Forum Presents \u2014 Revisiting the standard of care: The emerging role of low-molecular-weight heparin in cardiology practice. Presented at American College of Cardiology 46th Annual Scientific Sessions, Anaheim, CA, March 15, 1997."},{"key":"160718_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0002-9610(91)90183-E","volume":"162","author":"AF Aburahma","year":"1991","unstructured":"Aburahma AF, Boland JP, Witsberger T. Diagnostic and therapeutic strategies of white clot syndrome. Am J Surg 1991:162:175\u2013179.","journal-title":"Am J Surg"},{"key":"160718_CR18","first-page":"1565","volume":"320","author":"J. Hirsh","year":"1991","unstructured":"Hirsh J. Heparin. N Engl J Med 1991:320:1565\u20131574.","journal-title":"N Engl J Med"},{"key":"160718_CR19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007611-198805000-00018","volume":"81","author":"PE Stanton","year":"1988","unstructured":"Stanton PE, Evans JR, Lefemine AA, et al. White clot syndrome. Southern Med J 1988:81:616\u2013620.","journal-title":"Southern Med J"},{"key":"160718_CR20","first-page":"678","volume":"300","author":"IH Scheinberg","year":"1979","unstructured":"Scheinberg IH. Thrombocytopenic reaction to aspirin and acetaminophen. N Engl J Med 1979:300:678.","journal-title":"N Engl J Med"},{"key":"160718_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00000441-197402000-00008","volume":"267","author":"SK Garg","year":"1974","unstructured":"Garg SK, Sarker CR. Aspirin-induced thrombocytopenia on an immune basis. Am J Med Sci 1974:267:129\u201332.","journal-title":"Am J Med Sci"},{"key":"160718_CR22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/ard.22.6.440","volume":"22","author":"HO Nieweg","year":"1963","unstructured":"Nieweg HO, Bouma HGD, Vries KD, et al. Hematological side effects of some antirheumatic drugs. Ann Rheum Dis 1963:22:440\u2013443.","journal-title":"Ann Rheum Dis"},{"key":"160718_CR23","first-page":"609","volume":"1","author":"JR D'Eshouges","year":"1961","unstructured":"D'Eshouges JR, Griguer P, Smadja A, et al. Purpura thrombocytopenique aigu apr sensibilisation a l'aspirine. Nouv Rev Franc Hematol 1961:1:609\u2013611.","journal-title":"Nouv Rev Franc Hematol"},{"key":"160718_CR24","first-page":"323","volume":"26","author":"FHJ Class","year":"1984","unstructured":"Class FHJ, de Fraiture WH, Meyboom RHB. Thrombop\u00e9nie caus\u00e9e par des anticorps induits par la ticlopidine. Nouv Rev Franc Hematol 1984:26:323\u2013324.","journal-title":"Nouv Rev Franc Hematol"},{"key":"160718_CR25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199011223232114","volume":"323","author":"S Takeshita","year":"1990","unstructured":"Takeshita S, Kawazie N, Yoshida T, Fukiuama K. Ticlopidine and thrombocytopenia. N Engl J Med 1990:323:1487.","journal-title":"N Engl J Med"},{"key":"160718_CR26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0735-1097(93)90041-X","volume":"22","author":"NS Kleiman","year":"1993","unstructured":"Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis And Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993:22:381\u2013389.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl.","key":"160718_CR27","doi-asserted-by":"crossref","first-page":"80A","DOI":"10.1016\/0735-1097(95)91788-Y","volume":"00","author":"AM Lincoff","year":"1995","unstructured":"Lincoff AM, Tcheng JE, Bass TA, et al. for the PROLOG Investigators. J Am Coll Cardiol 1995:00(Suppl.):80A\u201381A.","journal-title":"J Am Coll Cardiol"},{"key":"160718_CR28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","volume":"330","author":"EPIC Investigators.","year":"1994","unstructured":"EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in highrisk coronary angioplasty. N Engl J Med 1994:330:956\u2013961.","journal-title":"N Engl J Med"},{"key":"160718_CR29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","volume":"349","author":"CAPTURE Investigators.","year":"1997","unstructured":"CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997:349:1429\u20131435.","journal-title":"Lancet"},{"key":"160718_CR30","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","volume":"336","author":"EPILOG Investigators.","year":"1997","unstructured":"EPILOG Investigators. Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997:336: 1689\u20131696.","journal-title":"N Engl J Med"},{"issue":"SupplA","key":"160718_CR31","doi-asserted-by":"crossref","first-page":"82A","DOI":"10.1016\/S0735-1097(96)80531-6","volume":"00","author":"SD Berkowitz","year":"1996","unstructured":"Berkowitz SD, Sane DC, Shavender JH, Sigmon KN, Toopol EJ, Califf RM, for the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) study group. Analysis of the occurrence and clinical significance of thrombocytopenia with c7E3 (abciximab) in the EPIC trial. J Am Coll Cardiol 1996:00(Suppl: A):82A.","journal-title":"J Am Coll Cardiol"},{"key":"160718_CR32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0002-9149(94)90474-X","volume":"74","author":"JD Boehrer","year":"1994","unstructured":"Boehrer JD Kereiakes DJ, Navetta FI, Califf RM, Topol EJ for the EPIC Investigators. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994:74: 1166\u20131170.","journal-title":"Am J Cardiol"},{"key":"160718_CR33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0002-9149(96)90072-7","volume":"78","author":"DJ Keriekas","year":"1996","unstructured":"Keriekas DJ, Essell J, Abbottsmith CE Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996:78:1161\u20131163.","journal-title":"Am J Cardiol"},{"key":"160718_CR34","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1021\/jm00042a007","volume":"37","author":"MS Egbertson","year":"1994","unstructured":"Egbertson MS, Chang CT, Duggan ME, et al. Non-peptide fibrinogen receptor antagonists 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994:37: 2537\u20132551.","journal-title":"J Med Chem"},{"key":"160718_CR35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","volume":"27","author":"DJ Keriekas","year":"1996","unstructured":"Keriekas DJ Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockage in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996:27:536\u2013542.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl.","key":"160718_CR36","first-page":"I553","volume":"94","author":"HV Anderson","year":"1996","unstructured":"Anderson HV, Betrand ME, Whitworth HB, Sax FL, Willerson JT, for the RESTORE Investigators. Bleeding risk with platelet inhibition using tirofiban: The RESTORE trial. Circulation 1996:94(Suppl.):I553.","journal-title":"Circulation"},{"key":"160718_CR37","unstructured":"White HD for the PRISM Investigators. Platelet receptor inhibition for ischemic syndrome management (PRISM). Presented at American College of Cardiology 46th Annual Scientific Sessions, Anaheim, CA, March 17, 1997."},{"key":"160718_CR38","unstructured":"Theroux P for the PRISM-PLUS Investigators. GP IIb\/IIIa antagonism with tirofiban in high risk unstable angina trial (PRISM-PLUS). Presented at American College of Cardiology 46th Annual Scientific Sessions, Anaheim, CA, March 17, 1997."},{"key":"160718_CR39","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.95.4.846","volume":"95","author":"EM Ohman","year":"1997","unstructured":"Ohman EM, Kleiman NS, Gacioch G, et al. for the IMPACTAMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb\/IIIa integrin receptor blockage with integrilin in acute myocardial infarction. Circulation 1997:95:846\u2013854.","journal-title":"Circulation"},{"key":"160718_CR40","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/01.CIR.91.8.2151","volume":"91","author":"JE Tcheng","year":"1995","unstructured":"Tcheng JE, Harrington RA, Kottke-Marchant K for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb\/IIIa blocker integrelin in elective coronary intervention. Circulation 1995:91:2151\u20132157.","journal-title":"Circulation"},{"key":"160718_CR41","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","volume":"349","author":"IMPACT-II Investigators.","year":"1997","unstructured":"IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997:349: 1422\u20131428.","journal-title":"Lancet"},{"key":"160718_CR42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.94.5.899","volume":"94","author":"P Theroux","year":"1996","unstructured":"Theroux P, Kouz S, Roy L et al. on behalf of the Investigators. Platelet membrane receptor glycoprotein IIb\/IIIa antagonism in unstable angina: The Canadian lamifiban study. Circulation 1996:94:899\u2013905.","journal-title":"Circulation"},{"issue":"Suppl.A","key":"160718_CR43","first-page":"410A","volume":"29","author":"RA Harrington","year":"1997","unstructured":"Harrington RA, Newby LK, Moliterno DJ, et al. for the PARAGON Investigators. J Am Coll Cardiol 1997:29(Suppl. A):410A.","journal-title":"J Am Coll Cardiol"},{"key":"160718_CR44","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/01.CIR.97.4.340","volume":"97","author":"CP Cannon","year":"1998","unstructured":"Cannon CP, Novotny WF, McCabe CH et al. for the TIMI 12 Investigators. Randomized trial of an oral glycoprotein IIb\/IIIa antagonist sibrafiban in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998:97:340\u2013349.","journal-title":"Circulation"},{"issue":"Suppl.I","key":"160718_CR45","first-page":"I232","volume":"90","author":"P Theroux","year":"1994","unstructured":"Theroux P, Kouz S, Knutdson ML et al. A randomized double-blind controlled trial with the non-peptidic platelet GP IIb\/IIIa antagonist RO 44-9883 in unstable angina. Circulation 1994:90(Suppl. I):I232.","journal-title":"Circulation"},{"key":"160718_CR46","doi-asserted-by":"crossref","first-page":"242A","DOI":"10.1016\/S0735-1097(96)81843-2","volume":"27","author":"C Simpfendorfer","year":"1996","unstructured":"Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GP IIb\/IIIa receptor blockage: A pilot study of xemilofiban an orally active antagonist in unstable angina. J Am Coll Cardiol 1996:27:242A.","journal-title":"J Am Coll Cardiol"},{"key":"160718_CR47","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/01.CIR.94.5.906","volume":"94","author":"DJ Kereiakes","year":"1996","unstructured":"Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Circulation 1996:94:906\u2013910.","journal-title":"Circulation"},{"issue":"SupplI.","key":"160718_CR48","first-page":"I201","volume":"88","author":"HD White","year":"1993","unstructured":"White HD, Charbonnier B, Van deWerf F, et al. An aspirin-controlled study of MK-852 in patients with unstable angina. Circulation 1993:88(Suppl I.):I201.","journal-title":"Circulation"},{"issue":"SupplI.","key":"160718_CR49","first-page":"I201","volume":"88","author":"P Theroux","year":"1993","unstructured":"Theroux P, Kleiman N, Shah PK, et al. A double-blind, heparin-controlled study of MK-852 in unstable angina. Circulation 1993:88(Suppl I.):I201.","journal-title":"Circulation"},{"issue":"SupplA","key":"160718_CR50","doi-asserted-by":"crossref","first-page":"94A","DOI":"10.1016\/S0735-1097(97)84112-5","volume":"31","author":"PC Deedwania","year":"1998","unstructured":"Deedwania PC, Ferguson JJ, Kereiakes DJ, et al. Sustained platelet GP IIb\/IIIa blockade with oral orbofiban: Interim safety and tolerability results of the SOAR study. J AmColl Cardio 1998:31(Suppl A):94A.","journal-title":"J AmColl Cardio"},{"issue":"SupplA","key":"160718_CR51","doi-asserted-by":"crossref","first-page":"93A","DOI":"10.1016\/S0735-1097(97)84111-3","volume":"31","author":"RP Giugliano","year":"1998","unstructured":"Giugliano RP, McCabe CH, Segueira RF, et al. Dose Ranging Study of Intravenous RPR 109891 in patients with acute coronary syndromes\u2014results of TIMI 15A. J Am Coll Cardiol 1998:31(Suppl A):93A.","journal-title":"J Am Coll Cardiol"},{"key":"160718_CR52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-126-4-199702150-00010","volume":"126","author":"American Society of Hematology ITP Practice Guideline Panel.","year":"1997","unstructured":"American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American Society of Hematology. Ann Intern Med 1997:126:319\u2013326.","journal-title":"Ann Intern Med"},{"key":"160718_CR53","first-page":"445","volume":"11","author":"RA. Goebel","year":"1993","unstructured":"Goebel RA. Thrombocytopenia. Hematol Oncol Emerg 1993:11:445\u2013464.","journal-title":"Hematol Oncol Emerg"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1008887708104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1008887708104\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1008887708104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:31:37Z","timestamp":1754638297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1008887708104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["160718"],"URL":"https:\/\/doi.org\/10.1023\/a:1008887708104","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}